文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

住院COVID-19患者预防性与治疗性抗凝比较:一项随机临床试验

Prophylactic vs Therapeutic Anticoagulation in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2026-09-01
一句话结论在住院COVID-19患者中,院内治疗性低分子肝素序贯出院后依度沙班60 mg/d至42天,与预防性抗凝序贯安慰剂相比,未显著降低死亡和/或血栓栓塞事件(HR 0.74,95%CI 0.38-1.48,P=0.40)。

HERO-19是一项前瞻性、评估者盲法、多中心、平行组(1:1)、安慰剂对照、优效性随机临床试验,纳入德国10所大学医院收治于ICU或非ICU病房的确诊COVID-19患者139例。实验组院内接受体重调整的低分子肝素治疗性抗凝,出院后口服依度沙班60 mg每日一次,对照组院内接受低分子肝素预防性抗凝,出院后安慰剂,疗程42天。主要终点(全因死亡和/或静脉血栓栓塞和/或动脉血栓栓塞)在治疗性抗凝组67例中发生14例(21%,2.31例/患者年),预防性抗凝组70例中发生20例(29%,3.37例/患者年),HR 0.74(95%CI 0.38-1.48,P=0.40),未达统计学显著;符合方案分析HR 0.66(95%CI 0.32-1.37,P=0.26)。出血事件治疗组7例、对照组6例。

要点

  • 住院COVID-19患者院内治疗性低分子肝素序贯出院后依度沙班60 mg/d至42天,主要终点(死亡和/或血栓栓塞)发生14/67例(21%)vs 预防性抗凝20/70例(29%),HR 0.74(95%CI 0.38-1.48,P=0.40),未达统计学显著。
  • 符合方案分析中治疗性抗凝组HR 0.66(95%CI 0.32-1.37,P=0.26),同样未达统计学显著。
  • 出血事件:治疗性抗凝组7例,预防性抗凝组6例,主要安全终点为ISTH标准的大出血和临床相关非大出血。
  • 研究纳入ICU或非ICU病房住院的COVID-19确诊患者,治疗性抗凝方案为院内体重调整低分子肝素、出院后依度沙班60 mg每日一次,总疗程42天。

适用人群与场景

  • 确诊COVID-19并住院于ICU或非ICU病房的成人患者,来自德国10所大学医院,纳入时间2020年11月12日至2023年1月15日。
  • 研究共纳入139例患者,平均(SD)年龄58.4(13.7)岁,男性93例(67%)、女性46例(33%)。

处置流程与药物剂量

  • 实验组:院内使用低分子肝素按体重调整进行治疗性抗凝,出院后口服依度沙班60 mg每日一次,总疗程42天。
  • 对照组:院内使用低分子肝素进行预防性抗凝作为标准治疗的一部分,出院后使用安慰剂,总疗程42天。

研究设计与关键结果

  • 研究类型:前瞻性、评估者盲法、多中心、平行组(1:1)、安慰剂对照、优效性随机临床试验(HERO-19),纳入139例住院COVID-19患者。
  • 主要终点(42天内全因死亡和/或静脉血栓栓塞和/或动脉血栓栓塞首次发生):治疗性抗凝组14/67例(21%,2.31例/患者年)vs 预防性抗凝组20/70例(29%,3.37例/患者年),HR 0.74(95%CI 0.38-1.48,P=0.40),未达统计学显著;2例患者主要终点评估不可用。
  • 符合方案分析:HR 0.66(95%CI 0.32-1.37,P=0.26)。
  • 出血事件:治疗性抗凝组7例,预防性抗凝组6例;主要安全终点为按ISTH标准定义的大出血和临床相关非大出血。

证据类型、等级与局限

  • 证据类型:前瞻性、评估者盲法、多中心、平行组、安慰剂对照、优效性随机临床试验(RCT)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在住院COVID-19患者中,院内治疗性低分子肝素序贯出院后依度沙班60 mg/d至42天,与预防性抗凝序贯安慰剂相比,未统计学显著降低死亡和/或血栓栓塞事件(HR 0.74,95%CI 0.38-1.48,P=0.40)。
  • 作者结论:在住院COVID-19患者中,院内治疗性低分子肝素序贯依度沙班至42天,与预防性抗凝序贯安慰剂相比,未统计学显著减少死亡和/或血栓栓塞事件。

指南或共识出处

  • ClinicalTrials.gov注册号:NCT04542408(HERO-19)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Coagulopathy in the context of COVID-19 is a major threat due to deep vein thromboses and pulmonary embolisms.

OBJECTIVE: To assess whether therapeutic anticoagulation on top of standard of care (SOC) compared with prophylactic anticoagulation as part of SOC can improve objective patient-relevant end points.

DESIGN, SETTING, AND PARTICIPANTS: This prospective, assessor-blinded, multicenter, parallel-group (1:1), placebo-controlled, superiority randomized clinical trial (HERO-19) assessed patients with a confirmed diagnosis of COVID-19 who were hospitalized in an intensive care unit or non-intensive care ward at 1 of 10 university hospitals in Germany from November 12, 2020, to January 15, 2023. Data analysis was conducted after the final database lock in February 2024.

INTERVENTIONS: Patients were treated for 42 days. Patients enrolled in the experimental group received therapeutic anticoagulation using low-molecular-weight heparin (LMWH) body weight adapted during the hospital stay and oral anticoagulation using edoxaban, 60 mg daily, after being discharged from the hospital. Patients enrolled in the control group received prophylactic anticoagulation using LMWH as part of SOC while in the hospital and placebo after discharge.

MAIN OUTCOMES AND MEASURES: The primary end point was time to the first occurrence of all-cause mortality and/or venous thromboembolism and/or arterial thromboembolism within up to 42 days. Potential thromboembolic events were assessed by duplex ultrasonography of arms and legs at day 14 or discharge and day 42. The primary safety outcome was major and clinically relevant nonmajor bleeding according to International Society on Thrombosis and Haemostasis classification.

RESULTS: A total of 139 patients (mean [SD] age, 58.4 [13.7] years; 93 [67%] male and 46 [33%] female) were included in the study. Of these, 71 patients (51%) were randomized to prophylactic anticoagulation group, whereas 68 (49%) were randomized to the therapeutic anticoagulation group. The primary outcome occurred in 14 of 67 patients (21%; 2.31 incidence per patient-year) assigned to therapeutic anticoagulation and 20 of 70 (29%; 3.37 incidence per patient-year) assigned to prophylactic anticoagulation (primary end point assessment not available for 2 patients) with primary end point assessment (hazard ratio, 0.74; 95% CI, 0.38-1.48; P = .40). In the per-protocol analysis, the hazard ratio was 0.66 (95% CI, 0.32-1.37; P = .26). A total of 7 bleeding events occurred in the intervention group, whereas 6 bleeding events occurred in the control group.

CONCLUSIONS AND RELEVANCE: In patients hospitalized with COVID-19, in-hospital therapeutic anticoagulation with LMWH followed by edoxaban to day 42 did not statistically significantly reduce death and/or thromboembolic events compared with prophylactic anticoagulation followed by placebo.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04542408.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Karakas M, Nicolay SS, Wichmann D, et al. Prophylactic vs Therapeutic Anticoagulation in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA Netw Open. 2026. PMID: 42776529. doi:10.1001/jamanetworkopen.2026.35333

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。